stent - antithrombotics - all type of patients clinical trials results meta-analysis

<h1> <a href="TM24-8-antithrombotics-stent" > <strong>stent</strong> - antithrombotics </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t8364.htm"> FANTASTIC, 1998 </a> <br> </td> <td> Ticlopidine 250 mg BID 6 wks Aspirin 100–325 mg qD<br>  <i>versus</i> <br> Coumadin INR† 2.5–3.0 6 wks Aspirin 100–325 mg qD/pj </td> <td> </td> <td> follow-up <br> n=243/230<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8365.htm"> ISAR, 1996 </a> <br> </td> <td> Ticlopidine 250 mg BID 4 wks Aspirin 100 mg BIDage/pj<br>  <i>versus</i> <br> Coumadin INR 3.5–4.5 4 wks Aspirin 100 mg BID </td> <td> </td> <td> follow-up <br> n=257/260<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8366.htm"> Foussas, 2000 </a> <br> </td> <td> Ticlopidine 500mg qD 1 mo Aspirin 325 mg qD<br>  <i>versus</i> <br> Coumadin INR 2–3 x4 wks Aspirin 325 mg qDg BID </td> <td> </td> <td> follow-up <br> n=203/201<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8367.htm"> MATTIS, 1998 </a> <br> </td> <td> Ticlopidine 250 mg BID 30 days Aspirin 250 mg qD<br>  <i>versus</i> <br> Coumadin INR 2.5–3.0 x30 days Aspirin 250 mg qDg qD/pj </td> <td> </td> <td> follow-up <br> n=177/173<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8368.htm"> STARS (vs coumadin+asp), 1998 </a> <br> </td> <td> Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD<br>  <i>versus</i> <br> Coumadin INR 2–2.5 x4 wks Aspirin 325 mg qDBID </td> <td> </td> <td> follow-up <br> n=546/550<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8369.htm"> STARS (vs aspirin), 1998 </a> <br> </td> <td> Ticlopidine 250 mg BID 4 wks Aspirin 325 mg qDDage/pj<br>  <i>versus</i> <br> Aspirin 325 mg qD </td> <td> </td> <td> follow-up <br> n=546/557<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8370.htm"> Hall, 1996 </a> <br> </td> <td> Ticlopidine 250 mg BID 1 mo Aspirin 325 mg qD 5 days<br>  <i>versus</i> <br> Aspirin 325 mg qD </td> <td> </td> <td> follow-up <br> n=13/103<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8371.htm"> Müller, 2000 </a> <br> </td> <td> Clopidogrel 75 mg qD x4 wks Aspirin 100 mg qD<br>  <i>versus</i> <br> Ticlopidine 250 mg BID x4 wks Aspirin 100 mg qD </td> <td> </td> <td> follow-up <br> n=355/345<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8372.htm"> CLASSICS, 2000 </a> <br> </td> <td> Clopidogrel 300mg x1, 75 mg qD x4 wks Aspirin 325 mg qDypñ ·`<br>  <i>versus</i> <br> Ticlopidine 250 mg BID x4 wks Aspirin 325 mg qD </td> <td> </td> <td> follow-up <br> n=345/340<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8373.htm"> TOPPS, 2001 </a> <br> </td> <td> Clopidogrel 300 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD<br>  <i>versus</i> <br> Ticlopidine 500 mg x1, unsp. Dose x2 wks Aspirin 325 mg qD </td> <td> </td> <td> follow-up <br> n=494/522<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8374.htm"> Piamsomboon, 2001 </a> <br> </td> <td> Clopidogrel 300 mg x1, 75 mg qD x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD<br>  <i>versus</i> <br> Ticlopidine 250 mg po BID x4 wks Aspirin 300 mg BID x4 wks, 300 mg qD </td> <td> </td> <td> follow-up <br> n=37/31<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8375.htm"> Kozuma, 2001 </a> <br> </td> <td> Cilostazol 200 mg qD x6 mos Aspirin 81–162 mg qD<br>  <i>versus</i> <br> Ticlopidine 200 mg qD x6 mos Aspirin 81–162 mg qD </td> <td> </td> <td> follow-up <br> n=62/63<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8376.htm"> Ochiai, 1999 </a> <br> </td> <td> Cilostazol 100 mg BID x6 mos Aspirin 81 mg TID<br>  <i>versus</i> <br> Ticlopidine 100 mg BID x1 mo Aspirin 81 mg TID </td> <td> </td> <td> follow-up <br> n=25/25<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8377.htm"> Park, 1999 </a> <br> </td> <td> Cilostazol 100 mg BID x6 mos Aspirin 200 mg qD<br>  <i>versus</i> <br> Ticlopidine 250 mg BID x4 wks Aspirin 200 mg qD </td> <td> </td> <td> follow-up <br> n=247/243<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8378.htm"> Yoon, 1999 </a> <br> </td> <td> Cilostazol 100 mg BID x30 days Aspirin 100 mg qD<br>  <i>versus</i> <br> Ticlopidine 250 mg BID x30 days Aspirin 100 mg qD </td> <td> </td> <td> follow-up <br> n=147/149<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8379.htm"> Kamishirado, 2002 </a> <br> </td> <td> Cilostazol 200 mg qD x6 mos Aspirin 81 mg qD<br>  <i>versus</i> <br> Ticlopidine 200 mg qD x6 mos Aspirin 81 mg qD </td> <td> </td> <td> follow-up <br> n=65/65<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8380.htm"> Sekiya, 1998 </a> <br> </td> <td> Cilostazol 200 mg qD x6mos Aspirin 81 mg qD<br>  <i>versus</i> <br> Coumadin unspecified regimen Aspirin 81 mg qD </td> <td> </td> <td> follow-up <br> n=63/63<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t8381.htm"> Kunishima, 1997 </a> <br> </td> <td> Cilostazol 200 mg qD unspecified durationg qD<br>  <i>versus</i> <br> Aspirin 81 mg qD </td> <td> </td> <td> follow-up <br> n=30/40<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t10357.htm"> CILON-T, 2010 </a> <br> </td> <td> triple antiplatelet therapy with aspirin, clopidogrel, and cilostazol for 6 month<br>  <i>versus</i> <br> dual antiplatelet therapy </td> <td> real-world patients undergoing PCI </td> <td> follow-up 6 mo<br> n=457/458<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="../TRC_t10411.htm"> DES-LATE, 2010 </a> <br> NCT00484926 </td> <td> dual antiplatelet therapy (clopidogrel plus aspirin)<br>  <i>versus</i> <br> aspirin alone </td> <td> patients who had received drug eluting stents and had been free of major adverse cardiac or cerebrovascular events and major bleeding for a period of at least 12 months </td> <td> follow-up 19.2 mo<br> n=1357/1344<br> Parallel groups<br> open <br> South Korea </td> </tr> <tr> <td> <a href="../TRC_t9470.htm"> ISAR-SAFE, 0 </a> <br> NCT00661206 </td> <td> additional 6 month period of clopidogrel<br>  <i>versus</i> <br> placebo </td> <td> Patients on clopidogrel therapy at least 6 months after DES implantation, who do not require a reintervention </td> <td> follow-up 12 months<br> n=-9/-9<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="../TRC_t9916.htm"> DAPT, </a> <br> NCT00977938 </td> <td> additional 18 months of thienopyridine treatment<br>  <i>versus</i> <br> placebo </td> <td> Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions </td> <td> follow-up <br> n=20645/0<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t10413.htm"> OPTIMIZED, </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t10415.htm"> GRAVITAS, </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t10416.htm"> ARTIC adjusted, </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t10417.htm"> ARTIC (extended dual antiplatelet), 0 </a> <br> NCT00827411 </td> <td> Pursuit of a dual oral antiplatelet therapy (aspirin and clopidogrel) beyond one year<br>  <i>versus</i> <br> Interruption of clopidogrel therapy after one year </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> </table> <h2>References</h2> <p> <b>FANTASTIC, 1998 : </b> Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EPRandomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. <i>Circulation 1998;98:1597-603</i> [PMID 9778323] </p> <p> <b>ISAR, 1996 : </b> Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm KA randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. <i>N Engl J Med 1996;334:1084-9</i> [PMID 8598866] </p> <p> <b>Foussas, 2000 : </b> Foussas S, Alexopoulos D, Stefanadis C, Olympios C, Voudris V, Hatzimiltiadis S, Sionis D, Vavouranakis E, Vrahatis A, Fakiolas C, Pissimisis E, Stefanidis A, Zairis M, Pavlides G, Vitakis S, Louridas G, Cokkinos D, Toutouzas PAntiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting. <i>Angiology 2000;51:289-94</i> [PMID 10778998] </p> <p> <b>MATTIS, 1998 : </b> Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard LRandomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). <i>Circulation 1998;98:2126-32</i> [PMID 9815866] </p> <p> <b>STARS (vs coumadin+asp), 1998 : </b> Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz REA clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. <i>N Engl J Med 1998;339:1665-71</i> [PMID 9834303] </p> <p> <b>STARS (vs aspirin), 1998 : </b> Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz REA clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. <i>N Engl J Med 1998;339:1665-71</i> [PMID 9834303] </p> <p> <b>Hall, 1996 : </b> Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, Ferraro M, Colombo AA randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. <i>Circulation 1996;93:215-22</i> [PMID 8548891] </p> <p> <b>Müller, 2000 : </b> Müller C, Büttner HJ, Petersen J, Roskamm HA randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. <i>Circulation 2000;101:590-3</i> [PMID 10673248] </p> <p> <b>CLASSICS, 2000 : </b> Bertrand ME, Rupprecht HJ, Urban P, Gershlick AHDouble-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). <i>Circulation 2000;102:624-9</i> [PMID 10931801] </p> <p> <b>TOPPS, 2001 : </b> Taniuchi M, Kurz HI, Lasala JMRandomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. <i>Circulation 2001;104:539-43</i> [PMID 11479250] </p> <p> <b>Piamsomboon, 2001 : </b> Piamsomboon C, Laothavorn P, Chatlaong B, Saguanwong S, Nasawadi C, Tanprasert P, Leelaprute M, Intayakorn U, Amornsak NEffectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation: 1 and 6-month follow-up. <i>J Med Assoc Thai 2001;84:1701-7</i> [PMID 11999816] </p> <p> <b>Kozuma, 2001 : </b> Kozuma K, Hara K, Yamasaki M, Morino Y, Ayabe S, Kuroda Y, Tanabe K, Ikari Y, Tamura TEffects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. <i>Am Heart J 2001;141:124-30</i> [PMID 11136497] </p> <p> <b>Ochiai, 1999 : </b> Ochiai M, Eto K, Takeshita S, Yokoyama N, Oshima A, Kondo K, Sato T, Isshiki TImpact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. <i>Am J Cardiol 1999;84:1074-6, A6, A9</i> [PMID 10569666] </p> <p> <b>Park, 1999 : </b> Park SW, Lee CW, Kim HS, Lee HJ, Park HK, Hong MK, Kim JJ, Park SJComparison of cilostazol versus ticlopidine therapy after stent implantation. <i>Am J Cardiol 1999;84:511-4</i> [PMID 10482146] </p> <p> <b>Yoon, 1999 : </b> Yoon Y, Shim WH, Lee DH, Pyun WB, Kim IJ, Jang Y, Cho SYUsefulness of cilostazol versus ticlopidine in coronary artery stenting. <i>Am J Cardiol 1999;84:1375-80</i> [PMID 10606107] </p> <p> <b>Kamishirado, 2002 : </b> Kamishirado H, Inoue T, Mizoguchi K, Uchida T, Nakata T, Sakuma M, Takayanagi K, Morooka SRandomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. <i>Am Heart J 2002;144:303-8</i> [PMID 12177649] </p> <p> <b>Sekiya, 1998 : </b> Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu HEffects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. <i>Am J Cardiol 1998;82:144-7</i> [PMID 9678282] </p> <p> <b>Kunishima, 1997 : </b> Kunishima T, Musha H, Eto F, Iwasaki T, Nagashima J, Masui Y, So T, Nakamura T, Oohama N, Murayama MA randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. <i>Clin Ther 1997;19:1058-66</i> [PMID 9385493] </p> <p> <b>ISAR-SAFE, 0 : </b> Byrne RA, Schulz S, Mehilli J, Iijima R, Massberg S, Neumann FJ, ten Berg JM, Schömig A, Kastrati ARationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. <i>Am Heart J 2009 Apr;157:620-4.e2</i> [PMID 19332187] 10.1016/j.ahj.2008.12.019 </p> <p> <b>DES-LATE, 2010 : </b> Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, LeDuration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents. <i>N Engl J Med 2010 Mar 15;:</i> [PMID 20231231] 10.1056/NEJMoa1001266 </p>